Palex Medical
-
DATABASE (104)
-
ARTICLES (95)
A plug&play digital health SaaS that connects remotely to medical devices, patients’ smartphones and sensors, which grew HumanITcare’s client base sixfold during Covid-19.
A plug&play digital health SaaS that connects remotely to medical devices, patients’ smartphones and sensors, which grew HumanITcare’s client base sixfold during Covid-19.
Pioneering AI SaaS combining virtual clinic and database for mental health professionals enables quicker diagnoses, with up to 90% accuracy.
Pioneering AI SaaS combining virtual clinic and database for mental health professionals enables quicker diagnoses, with up to 90% accuracy.
Co-founder of Therapixal
Pierre Fillard is Chief Science Officer and co-founder of Therapixel, creator of AI-powered breast cancer screening and diagnosis software MammoScreen. At Therapixel, he previously held the positions of CEO and CTO. Before founding Therapixel, Fillard was a senior research scientist at INRIA (National Institute for Research in Digital Science and Technology), where he focused on medical imaging and image processing. He has also been a visiting lecturer at CPE Lyon, a research associate at the French Alternative Energies and Atomic Agencies Commission, a PhD candidate at INRIA, and a research assistant at the University of North Carolina. He has a diploma from the HEC School of Management, a master’s in science, mathematics and computer science from the Université Jean Monnet Saint-Etienne and a degree in engineering, computer science, and applied mathematics from the Ecole Supérieure de Chimie Physique Electronique de Lyon.
Pierre Fillard is Chief Science Officer and co-founder of Therapixel, creator of AI-powered breast cancer screening and diagnosis software MammoScreen. At Therapixel, he previously held the positions of CEO and CTO. Before founding Therapixel, Fillard was a senior research scientist at INRIA (National Institute for Research in Digital Science and Technology), where he focused on medical imaging and image processing. He has also been a visiting lecturer at CPE Lyon, a research associate at the French Alternative Energies and Atomic Agencies Commission, a PhD candidate at INRIA, and a research assistant at the University of North Carolina. He has a diploma from the HEC School of Management, a master’s in science, mathematics and computer science from the Université Jean Monnet Saint-Etienne and a degree in engineering, computer science, and applied mathematics from the Ecole Supérieure de Chimie Physique Electronique de Lyon.
Founder and CEO of PesanLab
Dimas Prasetyo is the founder and CEO of PesanLab. He graduated with a degree in Medical Technology and Laboratory Science from Yogyakarta Health Polytechnic. He has over eight years of work experience in marketing, operations and management in the clinical laboratory diagnostics industry. He was also a product specialist at Non-invasive Genetic Abnormalities Test in Your Clinic and at Natera Inc. He co-founded Lab Panorama Bandung in 2009 and left in 2013 to become the founder of LabConX that was later rebranded as PesanLab.
Dimas Prasetyo is the founder and CEO of PesanLab. He graduated with a degree in Medical Technology and Laboratory Science from Yogyakarta Health Polytechnic. He has over eight years of work experience in marketing, operations and management in the clinical laboratory diagnostics industry. He was also a product specialist at Non-invasive Genetic Abnormalities Test in Your Clinic and at Natera Inc. He co-founded Lab Panorama Bandung in 2009 and left in 2013 to become the founder of LabConX that was later rebranded as PesanLab.
Samsung Venture Investment, or Samsung Ventures, is the VC investment arm of South Korean diversified conglomerate Samsung Group. It is a separate entity from Samsung NEXT.Samsung Ventures primarily invests in semiconductors, telecommunications tech, software and internet companies, as well as biotechnology and medical companies. The VC is built to support new innovations that can lead to further improvements in Samsung’s existing businesses, which includes smartphones, home appliances, and components like OLED panels and Li-ion batteries.Samsung Ventures has invested in healthcare and wellness tech companies like Indonesia’s telehealth service Alodokter, posture correction device makers Posture360, and Noom, an app for dieting and exercise. In the sensors front, Samsung Ventures has invested in Sense Photonics, a startup creating 3D computer vision based on lidar for industrial and automotive (self-driving) purposes. Besides these companies, Samsung Ventures has also invested in insurtech companies and even gaming companies, such as Pokémon Go developer Niantic.
Samsung Venture Investment, or Samsung Ventures, is the VC investment arm of South Korean diversified conglomerate Samsung Group. It is a separate entity from Samsung NEXT.Samsung Ventures primarily invests in semiconductors, telecommunications tech, software and internet companies, as well as biotechnology and medical companies. The VC is built to support new innovations that can lead to further improvements in Samsung’s existing businesses, which includes smartphones, home appliances, and components like OLED panels and Li-ion batteries.Samsung Ventures has invested in healthcare and wellness tech companies like Indonesia’s telehealth service Alodokter, posture correction device makers Posture360, and Noom, an app for dieting and exercise. In the sensors front, Samsung Ventures has invested in Sense Photonics, a startup creating 3D computer vision based on lidar for industrial and automotive (self-driving) purposes. Besides these companies, Samsung Ventures has also invested in insurtech companies and even gaming companies, such as Pokémon Go developer Niantic.
American investment capital firm Farallon Capital Management was established in 1986. The company manages equity capital for institutions, including college endowments, charitable foundations and pension plans, and funds for high net worth individuals. While most of its investments are in risk arbitrage and debt restructuring, it has also invested in startups across different verticals, such as Indonesian ride-hailing firm Gojek and a host of biotechnology, pharmaceuticals and medical technology companies.Farallon’s history with Indonesia began long before Gojek came into existence. In 2002, Farallon bought a controlling stake in Bank Central Asia (BCA), an Indonesian bank, during a time when investors avoided Indonesian banks that had been saddled with bad debt. With the controlling stake, Farallon installed a new bank chairman and reformed BCA. Over the next four years Farallon slowly divested in BCA and finally sold the remaining 4% stake in 2006 to earn a profit.
American investment capital firm Farallon Capital Management was established in 1986. The company manages equity capital for institutions, including college endowments, charitable foundations and pension plans, and funds for high net worth individuals. While most of its investments are in risk arbitrage and debt restructuring, it has also invested in startups across different verticals, such as Indonesian ride-hailing firm Gojek and a host of biotechnology, pharmaceuticals and medical technology companies.Farallon’s history with Indonesia began long before Gojek came into existence. In 2002, Farallon bought a controlling stake in Bank Central Asia (BCA), an Indonesian bank, during a time when investors avoided Indonesian banks that had been saddled with bad debt. With the controlling stake, Farallon installed a new bank chairman and reformed BCA. Over the next four years Farallon slowly divested in BCA and finally sold the remaining 4% stake in 2006 to earn a profit.
Co-founder, CTO of Meatable
Daan Luining is the Dutch co-founder and CTO at cell-based meat startup Meatable, the first to claim a highly scalable culture technology, where he has worked since 2018. He is also a research director at the Cellular Agriculture Society in Leiden, a joint initiative for cell-based startups to share knowledge and to collaborate on projects to further scale the sector. Luining is also on the board of directors at the not-for-profit Cultured Meat Foundation that promotes sector innovation. His past posts have all been in the area of research, either as a researcher or a technician, and at the same time as completing studies. His last job was as a research strategist at New York-based New Harvest, a callular food rsearch funding body, where he worked for a year and met Dr. Kotter, the inventor of Meatable’s cellular technology. His research positions from 2009–15 were in the area of cell culture, mass spectrometry and DNA sequencing at the Maastricht University, University Medical Center Amsterdam, Utrecht University and Leiden University. Luining holds a master’s in biological sciences from Leiden University in the Netherlands.
Daan Luining is the Dutch co-founder and CTO at cell-based meat startup Meatable, the first to claim a highly scalable culture technology, where he has worked since 2018. He is also a research director at the Cellular Agriculture Society in Leiden, a joint initiative for cell-based startups to share knowledge and to collaborate on projects to further scale the sector. Luining is also on the board of directors at the not-for-profit Cultured Meat Foundation that promotes sector innovation. His past posts have all been in the area of research, either as a researcher or a technician, and at the same time as completing studies. His last job was as a research strategist at New York-based New Harvest, a callular food rsearch funding body, where he worked for a year and met Dr. Kotter, the inventor of Meatable’s cellular technology. His research positions from 2009–15 were in the area of cell culture, mass spectrometry and DNA sequencing at the Maastricht University, University Medical Center Amsterdam, Utrecht University and Leiden University. Luining holds a master’s in biological sciences from Leiden University in the Netherlands.
Lei Ming graduated from Peking University (PKU) with a master's degree in Computer Science. While at university, he was a member of the PKU Sky Network search engine program. In 2000, Lei became one of the seven founding members of Baidu, where he led the search engine design and development team. Lei received his MBA from Stanford Business School in 2003. In 2005, he returned to China and started Kuwo Music, now one of the largest music platforms in China. As an angel investor, Lei focuses on the sectors of AI, consumption, education, medical services and entertainment.
Lei Ming graduated from Peking University (PKU) with a master's degree in Computer Science. While at university, he was a member of the PKU Sky Network search engine program. In 2000, Lei became one of the seven founding members of Baidu, where he led the search engine design and development team. Lei received his MBA from Stanford Business School in 2003. In 2005, he returned to China and started Kuwo Music, now one of the largest music platforms in China. As an angel investor, Lei focuses on the sectors of AI, consumption, education, medical services and entertainment.
Mayfield Fund is one of Silicon Valley's oldest venture capital firms. Founded by Wally Davis and Thomas J Davis Jr in 1969, the VC is based in Menlo Park, California.Current investments include CRISPR-focused companies like Mammoth Biosciences and biotech startup iLoF,l which is focused on creating a digital library of optical fingerprints for non-invasive patient screening, early diagnostics and personalized medical treatments.. With a total of $2.5bn assets under management, the firm focuses mainly on early-stage to growth-stage investments. The VC has also backed startups like Marketo, Lyft and SolarCity. Most of Mayfield’s exits took place during the 2008 financial crisis and through subsequent funds.In April 2020, amid the Covid-19 pandemic, Mayfield announced two new funds which raised $750m in total. Mayfield XVI will invest in early-stage companies, while Mayfield Select II will focus on growth-stage companies outside its portfolio. The company said last year that it has raised a similar size fund every four years and has invested in 30 companies per fund. It primarily leads Series A investments.
Mayfield Fund is one of Silicon Valley's oldest venture capital firms. Founded by Wally Davis and Thomas J Davis Jr in 1969, the VC is based in Menlo Park, California.Current investments include CRISPR-focused companies like Mammoth Biosciences and biotech startup iLoF,l which is focused on creating a digital library of optical fingerprints for non-invasive patient screening, early diagnostics and personalized medical treatments.. With a total of $2.5bn assets under management, the firm focuses mainly on early-stage to growth-stage investments. The VC has also backed startups like Marketo, Lyft and SolarCity. Most of Mayfield’s exits took place during the 2008 financial crisis and through subsequent funds.In April 2020, amid the Covid-19 pandemic, Mayfield announced two new funds which raised $750m in total. Mayfield XVI will invest in early-stage companies, while Mayfield Select II will focus on growth-stage companies outside its portfolio. The company said last year that it has raised a similar size fund every four years and has invested in 30 companies per fund. It primarily leads Series A investments.
CEO and co-founder of Kobo360
In 2011, young Obi Ozor used his savings and loans from his family and friends to set up Bezmo Global to import second-hand trucks from the US and sell them in Nigeria. Despite suffering from kidney failure issues, he managed to run the business for four years to earn money to pay for his medical treatments. He fully recovered and moved to Michigan to continue his education.At the University of Michigan, Ozor met Ife Oyedele II and the two friends started an e-commerce venture to sell diapers and baby soap from the US to customers in Nigeria. Ozor moved to the University of Pennsylvania and graduated with a BA International Relations and Finance at Wharton School of Business. In 2014, he gained some work experience in investment banking at JP Morgan in New York.In 2015, Ozor returned to Nigeria and joined Uber as operations coordinator. In 2016, the serial entrepreneur and his friend Oyedele co-founded Uber-style logistics platform Kobo360 in Lagos.
In 2011, young Obi Ozor used his savings and loans from his family and friends to set up Bezmo Global to import second-hand trucks from the US and sell them in Nigeria. Despite suffering from kidney failure issues, he managed to run the business for four years to earn money to pay for his medical treatments. He fully recovered and moved to Michigan to continue his education.At the University of Michigan, Ozor met Ife Oyedele II and the two friends started an e-commerce venture to sell diapers and baby soap from the US to customers in Nigeria. Ozor moved to the University of Pennsylvania and graduated with a BA International Relations and Finance at Wharton School of Business. In 2014, he gained some work experience in investment banking at JP Morgan in New York.In 2015, Ozor returned to Nigeria and joined Uber as operations coordinator. In 2016, the serial entrepreneur and his friend Oyedele co-founded Uber-style logistics platform Kobo360 in Lagos.
Co-founder of Meatable
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
COO and co-founder of iLoF
Mehak Mumtaz grew up in Pakistan and decided to study biochemistry when she saw her brother suffering from an unknown learning disability. Her parents, both medical doctors, could not get an accurate diagnosis for their son. In her search to understand the molecular mechanisms behind diseases, she applied to study at the University of Oxford. In 2008, she was granted the Reach Oxford Scholarship and graduated with a master’s in biochemistry in 2012. In 2015, the St Hilda’s alumna worked as an undergraduate tutor at Oxford while completing a PhD in pathology, specializing in oncology and cancer biology.In 2018, she worked on a rare cancer project as EIT Health Business Innovation fellow for a year. She left academia and joined a three-month bioentrepreneur bootcamp in Munich and a one-month Lev8 Woman Program at her alma mater’s Oxford Foundry. She joined EY-Parthenon in London as a strategy consultant in April 2019.In 2019, Mumtaz also met the iLoF co-founding team at the EIT Health Wild Card venture-building program. iLoF is a medtech startup that focuses on personalized medicine through the use of AI and photonics to create optical fingerprints in a cloud-based library to gather and manages disease biomarkers and biological profiles.She joined iLoF as COO and co-founder in December 2019 and left her full-time consultancy role at EY in March 2020.
Mehak Mumtaz grew up in Pakistan and decided to study biochemistry when she saw her brother suffering from an unknown learning disability. Her parents, both medical doctors, could not get an accurate diagnosis for their son. In her search to understand the molecular mechanisms behind diseases, she applied to study at the University of Oxford. In 2008, she was granted the Reach Oxford Scholarship and graduated with a master’s in biochemistry in 2012. In 2015, the St Hilda’s alumna worked as an undergraduate tutor at Oxford while completing a PhD in pathology, specializing in oncology and cancer biology.In 2018, she worked on a rare cancer project as EIT Health Business Innovation fellow for a year. She left academia and joined a three-month bioentrepreneur bootcamp in Munich and a one-month Lev8 Woman Program at her alma mater’s Oxford Foundry. She joined EY-Parthenon in London as a strategy consultant in April 2019.In 2019, Mumtaz also met the iLoF co-founding team at the EIT Health Wild Card venture-building program. iLoF is a medtech startup that focuses on personalized medicine through the use of AI and photonics to create optical fingerprints in a cloud-based library to gather and manages disease biomarkers and biological profiles.She joined iLoF as COO and co-founder in December 2019 and left her full-time consultancy role at EY in March 2020.
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
CEO and Founder of Didimo
Argentinian-born Verónica Costa Orvalho is a veteran in animation technology. In 2016, she became the CEO and founder of Didimo that was inspired by an earlier venture Face In Motion, established in 2007 to focus on cinematic quality and animation production of faces. Orvalho won the award for the AI and virtual reality category at a Women Startup Challenge event held in New York in 2017. Orvalho has a long academic track record in related fields, beginning with a first degree in Software Engineering from the University of Belgrano in Buenos Aires. She moved to Barcelona and obtained a master's degree in Videogame Design and Development at University Pompeu Fabra where she continued to work on creating a facial animation system “For CG Films”. She later completed her PhD at the Polytechnic University of Catalonia with her thesis: Fast and Reusable Facial Rigging and Animation to develop an application that could speed up the traditional “slowing rigging” process. She has worked at Ericsson as a systems analyst and was a producer at the Argentinian film company Patagonik Film Group that helped to produce the Oscar-winning movie El hijo de la novia. She worked for four years as the founder of Panorama Consulting, a consultancy focusing on developing systems for the medical, logistics and entertainment industries. Since 2003, she has lectured in different institutions, including Porto University's Porto Interactive Center as its specialist in facial animation since 2008.
Argentinian-born Verónica Costa Orvalho is a veteran in animation technology. In 2016, she became the CEO and founder of Didimo that was inspired by an earlier venture Face In Motion, established in 2007 to focus on cinematic quality and animation production of faces. Orvalho won the award for the AI and virtual reality category at a Women Startup Challenge event held in New York in 2017. Orvalho has a long academic track record in related fields, beginning with a first degree in Software Engineering from the University of Belgrano in Buenos Aires. She moved to Barcelona and obtained a master's degree in Videogame Design and Development at University Pompeu Fabra where she continued to work on creating a facial animation system “For CG Films”. She later completed her PhD at the Polytechnic University of Catalonia with her thesis: Fast and Reusable Facial Rigging and Animation to develop an application that could speed up the traditional “slowing rigging” process. She has worked at Ericsson as a systems analyst and was a producer at the Argentinian film company Patagonik Film Group that helped to produce the Oscar-winning movie El hijo de la novia. She worked for four years as the founder of Panorama Consulting, a consultancy focusing on developing systems for the medical, logistics and entertainment industries. Since 2003, she has lectured in different institutions, including Porto University's Porto Interactive Center as its specialist in facial animation since 2008.
Nuuk, the cooler box poised to disrupt cold chain logistics
Barcelona-based startup Groenlandia Tech has developed a smart cooler box to track and monitor biological samples, providing an extra layer of security and control during transport
Mediktor: AI medical diagnosis app wants to improve global health outcomes
NLP-based triage and diagnosis tool has achieved a 91% accuracy rate in clinical trials and raised €3 million funding
China’s medical exoskeleton startups take on a promising but challenging market
It was not until 2018 that the first China-made lower limb exoskeleton got regulatory clearance at home, around the same time the first Chinese rehabilitation robot got US FDA approval
BioMind: AI medical diagnostics with over 90% accuracy for 100 diseases
BioMind helps doctors save lives by providing more accurate diagnosis of life-threatening diseases like Covid-19 and brain tumors
TMiRob's medical robots lighten the load of doctors and nurses in hospitals
The robots also reach an operating room three minutes faster than human nurses – that's more time for saving lives
Medigo teams up with Indonesian Medical Association to launch primary care clinic network
Medigo aims to support healthcare operators with its clinic management SaaS, booking and medical records app for patients and more
For your X-ray records, just check the cloud
A Chinese startup has built a digital medical image library on the cloud, bringing ease and cost savings to patients, doctors and hospitals countrywide
YITU takes smart healthcare to the next level
AI programs developed by this Chinese medtech startup provide more accurate diagnoses by reading medical images in conjunction with patients’ medical records
Backed by pharmas, doctors, medtech startup DyCare is expanding fast across Europe
Its remote musculoskeletal rehabilitation and monitoring system sets to improve rehabilitation outcomes in an overtaxed sector
HigoSense launching advanced mobile device for self-triage and diagnosis, boosting telemedicine
The Polish medtech has developed a five-in-one diagnostic device for throat, ear, heart checks and more, with diagnosis in four minutes and compatible with diagnostic equipment
UpHill: Helping doctors put the latest research into practice
Born out of practitioners’ difficulty in keeping up with latest treatments and protocols, UpHill now includes guidance on Covid-19
China's WeDoctor offers free coronavirus consultations globally in English and Chinese
WeDoctor lets anyone in the world send queries to doctors who fought to save lives in China's most affected Covid-19 districts, and now helping people overseas to stay safe during the pandemic
Icaria Medical's CardioSense: Cardiovascular pre-diagnosis in less than 60 seconds
Icaria Medical is seeking clinical validation and funding for its AI-based monitor, which measures blood pressure continuously and non-invasively
As more Chinese opt for cosmetic surgery, startups have emerged to help them make informed decisions
China’s medical aesthetic services platforms face both opportunities and challenges with the rise of Generation Z
Tonic App: Just the tonic for overburdened doctors
CEO Daniela Seixas and COO Gonçalo Vilaça discussed Tonic App, their free solution for streamlining administrative tasks in the medical sector
Sorry, we couldn’t find any matches for“Palex Medical”.
POPULAR DATABASE
